Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Innoviva Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Armata Pharmaceuticals Inc. June 11, 202699.2%
-
Armata Pharmaceuticals Inc. June 12, 202599.7%
-
Armata Pharmaceuticals Inc. June 12, 202499.3%
-
Armata Pharmaceuticals Inc. September 14, 202399.0%
-
Innoviva Inc. May 22, 202398.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 10, 2026 | Armata Pharmaceuticals Inc. | Shares withheld for tax | −14,041 | $4.26 | $59,815 |
| Mar 14, 2026 | Armata Pharmaceuticals Inc. | Shares withheld for tax | −4,919 | $10.54 | $51,846 |
| Jul 10, 2025 | Armata Pharmaceuticals Inc. | Shares withheld for tax | −13,637 | $2.27 | $30,956 |
| Mar 14, 2025 | Armata Pharmaceuticals Inc. | Shares withheld for tax | −6,061 | $1.95 | $11,819 |
| Jul 10, 2024 | Armata Pharmaceuticals Inc. | Shares withheld for tax | −22,925 | $2.68 | $61,439 |
| Mar 14, 2024 | Armata Pharmaceuticals Inc. | Grant or award | +60,000 | — | — |
| Dec 21, 2023 | Armata Pharmaceuticals Inc. | Grant or award | +200,000 | — | — |
| May 22, 2023 | Innoviva Inc. | Grant or award | +16,495 | — | — |
Questions about Deborah Birx
What boards is Deborah Birx on?
Deborah Birx sits on the boards of Armata Pharmaceuticals Inc. and Innoviva Inc.
What company is Deborah Birx the CEO of?
Deborah Birx has been Chief Executive Officer of Armata Pharmaceuticals Inc. since July 2023.
How long has Deborah Birx served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.